{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-005096","form_type":"8-K","ticker":"OCEA","cik":"0001869974","company_name":"Ocean Biomedical, Inc.","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.285219+00:00","generated_at":"2026-06-19T12:12:13.152221+00:00","sec_items":["1.01","2.01","5.02","3.02","9.01","4.01","2.03","3.03","5.01","5.03","5.05","5.06"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Ocean Biomedical completes merger with Aesther; begins trading Feb 15 under OCEA","bullets":["Legacy Ocean holders received ~23.36M shares valued at ~$233.6M at $10/share in merger.","Public stockholders redeemed 10.39M shares at ~$10.56/share, paying ~$58.85M from trust.","Earnout: up to 19M additional shares if VWAP exceeds $15, $17.50, or $20 over 36 months.","Post-combination shares: 34.76M common; warrants for 11.28M shares.","Lock-up agreements with Poseidon Bio and Dr. Kathuria for one year or price condition met."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-005096","json":"https://secwatch.observer/filing/0001493152-23-005096.json","markdown":"https://secwatch.observer/filing/0001493152-23-005096.md","text":"https://secwatch.observer/filing/0001493152-23-005096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T12:12:13.152221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d1c50ee39","claim":"Elizabeth Ng was appointed as Chief Executive Officer and Class III Director at Ocean Biomedical, Inc..","evidence_excerpt":"Elizabeth Ng, MBA 66 Chief Executive Officer and Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and Class III Director"}],"fact_type":"executive_change"},{"claim_id":"158cc14f0b","claim":"Chirinjeev Kathuria was appointed as Founder, Executive Chairman, Class III Director at Ocean Biomedical, Inc..","evidence_excerpt":"Dr. Chirinjeev Kathuria, M.D. 58 Founder, Executive Chairman, Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Founder, Executive Chairman, Class III Director"}],"fact_type":"executive_change"},{"claim_id":"2dea61b9b8","claim":"Daniel Behr was appointed as Executive Vice President and Head of External Innovation and Academic Partnerships at Ocean Biomedical, Inc..","evidence_excerpt":"Daniel Behr, MBA 64 Executive Vice President and Head of External Innovation and Academic Partnerships","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Head of External Innovation and Academic Partnerships"}],"fact_type":"executive_change"},{"claim_id":"6d8db12513","claim":"William Owens was appointed as Class I Director at Ocean Biomedical, Inc..","evidence_excerpt":"William Owens (1)(3) 72 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"6ed130437b","claim":"Inderjote Kathuria was appointed as Chief Strategy Officer at Ocean Biomedical, Inc..","evidence_excerpt":"Inderjote Kathuria, M.D. 56 Chief Strategy Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Strategy Officer"}],"fact_type":"executive_change"},{"claim_id":"78fef218db","claim":"Martin D. Angle was appointed as Class II Director at Ocean Biomedical, Inc..","evidence_excerpt":"Martin D. Angle (1)(2) 72 Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"9ca7a38b65","claim":"Jonathan Kurtis was appointed as Class I Director at Ocean Biomedical, Inc..","evidence_excerpt":"Jonathan Kurtis, M.D., Ph.D. 55 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"a55722db7e","claim":"Robert Sweeney was appointed as Chief Accounting Officer at Ocean Biomedical, Inc..","evidence_excerpt":"Robert Sweeney 57 Chief Accounting Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"a9b7ba349f","claim":"Michelle Berrey was appointed as Class I Director at Ocean Biomedical, Inc..","evidence_excerpt":"Michelle Berrey, M.D., MPH (1)(2)(3) 56 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"c791584fa4","claim":"Suren Ajjarapu departed as Chairman and Chief Executive Officer at Ocean Biomedical, Inc..","evidence_excerpt":"Suren Ajjarapu served as Aesther’s Chairman and Chief Executive Officer from Aesther’s inception in June 2021 until the Closing of the Business Combination.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Role","value":"Chairman and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d17c876f5b","claim":"Michael Peterson departed as Board Member at Ocean Biomedical, Inc..","evidence_excerpt":"Michael L. Peterson served on Aesther’s board of directors from September 2021 until the Business Combination.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Role","value":"Board Member"}],"fact_type":"executive_change"},{"claim_id":"d2a8056d14","claim":"Jack A. Elias was appointed as Class II Director at Ocean Biomedical, Inc..","evidence_excerpt":"Dr. Jack A. Elias, M.D. 71 Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"d6d76b4257","claim":"Michael Peterson was appointed as Class II Director at Ocean Biomedical, Inc..","evidence_excerpt":"Michael Peterson 60 Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"dd4f511cdf","claim":"Jerome Ringo was appointed as Class I Director at Ocean Biomedical, Inc..","evidence_excerpt":"Jerome Ringo (2)(3) 67 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"e1bf5d070a","claim":"Suren Ajjarapu was appointed as Class III Director at Ocean Biomedical, Inc..","evidence_excerpt":"Suren Ajjarapu 52 Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"e39e96a1c7","claim":"Gurinder Kalra was appointed as Chief Financial Officer at Ocean Biomedical, Inc..","evidence_excerpt":"Gurinder Kalra, MBA 57 Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"0f54ce23ef872449a4995a1469116b516d4a2d64","claim":"Ocean Biomedical, Inc.: Amended and restated bylaws to make changes appropriate for a public operating company, including provisions for special meetings, proxy solicitation, director vacancies, board committees, and stockholder proposals.","evidence_excerpt":"upon the Closing, pursuant to the terms of the Business Combination Agreement, Aesther amended and restated its bylaws to make certain changes that the Board deems appropriate for a public operating company, including, but not limited to, changes to provisions relating to special meetings in lieu of annual meetings, proxy solicitation and voting, director vacancies and removals, Board committees and stockholder proposals.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"8c2c31b9aa8c86d624adfce5590eed2e80e69417","claim":"Ocean Biomedical, Inc.: Amended Certificate filed with the Secretary of State of Delaware, effecting changes to the company's capital stock rights as described in the Proxy Statement.","evidence_excerpt":"On the Closing Date, Aesther filed its Amended Certificate with the Secretary of State of the State of Delaware.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"a1b5689b8df3807c30c498d42401589d42a4a927","claim":"Ocean Biomedical, Inc.: Company expects the Board to adopt and approve a new Code of Business Conduct and Ethics applicable to all employees, officers, and directors.","evidence_excerpt":"the Company expects the Board to adopt and approve a new Code of Business Conduct and Ethics applicable to all employees, officers, and directors of the Company.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.7,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"}],"fact_type":"governance_change"},{"claim_id":"a34bf0e6ccf65bca4388c474dc9101d2a7e08cc4","claim":"Ocean Biomedical, Inc.: Company ceased to be a shell company as a result of the Business Combination.","evidence_excerpt":"As a result of the Business Combination, the Company ceased to be a shell company as of the Closing.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"shell status"}],"fact_type":"governance_change"},{"claim_id":"a197e3a7e1a4a40c2469bcac67a389483bf2fafc","claim":"Ocean Biomedical, Inc. underwent a change of control involving Legacy Ocean for $233,554,320 (closed 2023-02-14).","evidence_excerpt":"as of immediately prior to the Closing approximately 23,355,432 shares of the Company’s Class A common stock (with a per-share value of $10.00) with an aggregate value equal to $233,554,320, as adjusted as required by the Business Combination Agreement to take into account net working capital, closing net debt and Legacy Ocean’s transaction expenses, in exchange for","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005096/0001493152-23-005096-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Legacy Ocean"},{"label":"Consideration","value":"$233,554,320"},{"label":"Closing","value":"2023-02-14"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}